Hck as a therapeutic target in myd88 mutated diseases
AssigneeDana-Farber Cancer Institute, Inc.
InventorsSteven P. Treon, Nathanael S Gay, Sara Jean Buhriage, Guang Yang, Jinhua Wang, Li Tan
Life of this patent
Estimating the term…
Loading patent…
AssigneeDana-Farber Cancer Institute, Inc.
InventorsSteven P. Treon, Nathanael S Gay, Sara Jean Buhriage, Guang Yang, Jinhua Wang, Li Tan
Estimating the term…
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., HCK, BTK, LYN, BLK, FRK) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating diseases (e.g., proliferative diseases) in a subject in need thereof).
A compound of Formula (I):
4-5. (canceled)
7-8. (canceled)
10-11. (canceled)
13-48. (canceled)
52-54. (canceled)
(canceled)
60-64. (canceled)
66-67. (canceled)
The method of claim 6759, wherein, the cancer is activated B-cell-like (ABC)-DLBCL.
69-89. (canceled)
92-106. (canceled)
Dependencies are inferred from the claim text.